CL2022002296A1 - Anticuerpos novedosos - Google Patents
Anticuerpos novedososInfo
- Publication number
- CL2022002296A1 CL2022002296A1 CL2022002296A CL2022002296A CL2022002296A1 CL 2022002296 A1 CL2022002296 A1 CL 2022002296A1 CL 2022002296 A CL2022002296 A CL 2022002296A CL 2022002296 A CL2022002296 A CL 2022002296A CL 2022002296 A1 CL2022002296 A1 CL 2022002296A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- novel antibodies
- methods
- tcr
- gamma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2002581.3A GB202002581D0 (en) | 2020-02-24 | 2020-02-24 | Novel antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002296A1 true CL2022002296A1 (es) | 2023-03-31 |
Family
ID=70108379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002296A CL2022002296A1 (es) | 2020-02-24 | 2022-08-23 | Anticuerpos novedosos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20230159638A1 (https=) |
| EP (3) | EP4591882A3 (https=) |
| JP (2) | JP2023516925A (https=) |
| KR (2) | KR20220145894A (https=) |
| CN (2) | CN115697401A (https=) |
| AU (2) | AU2021228266A1 (https=) |
| BR (2) | BR112022016894A2 (https=) |
| CA (2) | CA3168973A1 (https=) |
| CL (1) | CL2022002296A1 (https=) |
| CO (2) | CO2022013542A2 (https=) |
| EC (1) | ECSP22074030A (https=) |
| GB (1) | GB202002581D0 (https=) |
| IL (2) | IL295852A (https=) |
| MX (2) | MX2022010383A (https=) |
| PE (1) | PE20230438A1 (https=) |
| WO (2) | WO2021171002A1 (https=) |
| ZA (1) | ZA202209699B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202006989D0 (en) * | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| AU2022222299A1 (en) | 2021-02-17 | 2023-09-07 | F-Star Therapeutics Limited | Multispecific anti-tcr delta variable 1 antibodies |
| CN119080924B (zh) * | 2024-07-04 | 2025-02-25 | 上海交通大学医学院附属第九人民医院 | 一种单克隆免疫球蛋白及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016081518A2 (en) * | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
| AU2016274633B2 (en) * | 2015-06-09 | 2022-04-21 | Gammadelta Therapeutics Ltd | Methods for the production of TCR gamma delta+ T cells |
| EP3454870A4 (en) * | 2016-05-12 | 2020-03-04 | Adicet Bio Inc. | METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| CA3145523A1 (en) * | 2019-08-16 | 2021-02-25 | GammaDelta Therapeutics Limited | Therapeutic uses of anti-tcr delta variable 1 antibodies |
-
2020
- 2020-02-24 GB GBGB2002581.3A patent/GB202002581D0/en not_active Ceased
-
2021
- 2021-02-24 EP EP25177102.8A patent/EP4591882A3/en active Pending
- 2021-02-24 PE PE2022001812A patent/PE20230438A1/es unknown
- 2021-02-24 WO PCT/GB2021/050459 patent/WO2021171002A1/en not_active Ceased
- 2021-02-24 AU AU2021228266A patent/AU2021228266A1/en active Pending
- 2021-02-24 WO PCT/GB2021/050460 patent/WO2021171003A1/en not_active Ceased
- 2021-02-24 JP JP2022550778A patent/JP2023516925A/ja active Pending
- 2021-02-24 AU AU2021225390A patent/AU2021225390A1/en active Pending
- 2021-02-24 KR KR1020227033455A patent/KR20220145894A/ko active Pending
- 2021-02-24 MX MX2022010383A patent/MX2022010383A/es unknown
- 2021-02-24 CN CN202180028136.1A patent/CN115697401A/zh active Pending
- 2021-02-24 CA CA3168973A patent/CA3168973A1/en active Pending
- 2021-02-24 EP EP21709757.5A patent/EP4110813A1/en active Pending
- 2021-02-24 MX MX2022010239A patent/MX2022010239A/es unknown
- 2021-02-24 KR KR1020227029501A patent/KR20220164473A/ko active Pending
- 2021-02-24 US US17/904,890 patent/US20230159638A1/en active Pending
- 2021-02-24 BR BR112022016894A patent/BR112022016894A2/pt unknown
- 2021-02-24 US US17/801,786 patent/US20230090901A1/en active Pending
- 2021-02-24 JP JP2022550813A patent/JP2023514437A/ja active Pending
- 2021-02-24 EP EP21709758.3A patent/EP4110387B1/en active Active
- 2021-02-24 BR BR112022016671A patent/BR112022016671A2/pt unknown
- 2021-02-24 CN CN202180030584.5A patent/CN115461369A/zh active Pending
- 2021-02-24 IL IL295852A patent/IL295852A/en unknown
- 2021-02-24 CA CA3172340A patent/CA3172340A1/en active Pending
- 2021-02-24 IL IL295696A patent/IL295696A/en unknown
-
2022
- 2022-08-23 CL CL2022002296A patent/CL2022002296A1/es unknown
- 2022-08-30 ZA ZA2022/09699A patent/ZA202209699B/en unknown
- 2022-09-21 CO CONC2022/0013542A patent/CO2022013542A2/es unknown
- 2022-09-22 CO CONC2022/0013633A patent/CO2022013633A2/es unknown
- 2022-09-22 EC ECSENADI202274030A patent/ECSP22074030A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022013542A2 (es) | 2022-10-11 |
| BR112022016671A2 (pt) | 2022-11-16 |
| CO2022013633A2 (es) | 2023-02-16 |
| JP2023514437A (ja) | 2023-04-05 |
| CN115697401A (zh) | 2023-02-03 |
| AU2021228266A1 (en) | 2022-10-13 |
| EP4591882A2 (en) | 2025-07-30 |
| EP4591882A3 (en) | 2025-10-15 |
| ECSP22074030A (es) | 2022-10-31 |
| CA3172340A1 (en) | 2021-09-02 |
| MX2022010239A (es) | 2022-11-14 |
| PE20230438A1 (es) | 2023-03-08 |
| MX2022010383A (es) | 2022-09-05 |
| IL295852A (en) | 2022-10-01 |
| WO2021171002A1 (en) | 2021-09-02 |
| EP4110387A1 (en) | 2023-01-04 |
| CN115461369A (zh) | 2022-12-09 |
| AU2021225390A1 (en) | 2022-09-22 |
| BR112022016894A2 (pt) | 2023-04-04 |
| WO2021171003A1 (en) | 2021-09-02 |
| CA3168973A1 (en) | 2021-09-02 |
| EP4110813A1 (en) | 2023-01-04 |
| US20230090901A1 (en) | 2023-03-23 |
| EP4110387B1 (en) | 2025-05-21 |
| KR20220145894A (ko) | 2022-10-31 |
| JP2023516925A (ja) | 2023-04-21 |
| US20230159638A1 (en) | 2023-05-25 |
| IL295696A (en) | 2022-10-01 |
| GB202002581D0 (en) | 2020-04-08 |
| ZA202209699B (en) | 2024-12-18 |
| KR20220164473A (ko) | 2022-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002296A1 (es) | Anticuerpos novedosos | |
| CY1124091T1 (el) | Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας | |
| MX2020008336A (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. | |
| CL2020001726A1 (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| PE20071312A1 (es) | Anticuerpos contra il-22 humana | |
| CL2021002792A1 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| ECSP21046333A (es) | Anticuerpos humanizados contra la región de la cadena beta de la 9na familia trbv9 del tcr humano y sus métodos de uso | |
| BR112022003635A2 (pt) | Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso | |
| AR086984A1 (es) | Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer | |
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| MX2023000547A (es) | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas. | |
| CO2024009846A2 (es) | Anticuerpos de afinidad alta de dominio único y métodos de uso de estos | |
| AR119866A1 (es) | Desarrollo de una plataforma de hibridoma eficaz para descubrimiento de anticuerpos terapéuticos | |
| BR112022021077A2 (pt) | Anticorpos humanizados antifator bb de complemento e uso dos mesmos | |
| CO2026000998A2 (es) | Anticuerpos anti-proteína a-beta, métodos y usos de estos | |
| WO2020237092A3 (en) | Mmp-9 antibodies and methods of use thereof | |
| MX2024002408A (es) | Moléculas de unión al antígeno y usos de estas. | |
| MX2022010915A (es) | Anticuerpos anti-cd19, metodos de uso y fabricacion de los mismos. | |
| MX2020013243A (es) | Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos. | |
| CL2022002569A1 (es) | Dominios variables de anticuerpos dirigidos al receptor nkg2d | |
| EA202091053A1 (ru) | Модифицированные c- и ch1-домены | |
| PY2251665A (es) | Anticuerpo biespecífico aislado que se une específicamente a cd47 y pd-l1 | |
| CO2025003205A2 (es) | Anticuerpos anti-lair1 humano | |
| PY2530271A (es) | Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a bdca-2, y uso del mismo | |
| CU20230043A7 (es) | Anticuerpos biespecíficos que unen cd3 y el gangliósido ngcgm3 |